Providing New Beginnings to
Branded Pharmaceutical Portfolios
About Ibere Pharmaceuticals
Our principals have built transformational growth companies by leveraging deep industry relationships developed using our PATCOL® philosophy (People Are The Currency Of Life) and by applying our extensive knowledge of pharmaceutical operations.
Our management team’s capability spans from managing strong, internationally known brands, to developing clinical assets through the Food and Drug Administration (FDA) through to commercialization, to developing and applying technologies with industry-wide commercial applications.
Recent News and Press
PHILADELPHIA, April 19, 2021 /PRNewswire/ — Ibere Pharmaceuticals (the “Company”) today announced that, commencing April 19, 2021, holders of the units sold in the Company’s initial public offering of 13,800,000 units at $10.00 per unit, completed on March 2, 2021, may elect to separately trade the Class A ordinary shares and redeemable warrants included in the units. Those units not separated […]
Philadelphia, PA, March 2, 2021 – Ibere Pharmaceuticals (the “Company”) announced today that it closed its initial public offering of 13,800,000 units at $10.00 per unit, which included the exercise in full of the underwriter’s over-allotment option to purchase 1,800,000 Units. The offering resulted in gross proceeds to the Company of $138 million. The Company’s […]
A Philadelphia-based blank check company formed to pursue acquisitions in the life sciences industry has completed a $120 million initial public stock offering. Ibere Pharmaceuticals sold 12 million units at $10 per unit on Friday. Each unit consisted of one Class A ordinary share of the company and one-half of one redeemable warrant, with each […]
